| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-Lys-OAll.HCl is classified as a protected amino acid and does not have a specific biological receptor target. Its primary application is as a building block for introducing lysine residues with orthogonal C-terminal protection during Fmoc SPPS. The allyl ester provides protection for the C-terminus that is stable to Fmoc deprotection conditions but removable by palladium-catalyzed deallylation.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity for Fmoc-Lys-OAll.HCl is primarily as a peptide synthesis reagent. Amino acid derivatives have been commercially used as ergogenic supplements, influencing anabolic hormone secretion, fuel availability, mental performance, and prevention of muscular damage. Fmoc-Lys-OAll.HCl itself is not directly biologically active. Its utility is in preparing lysine-containing peptides for subsequent biological evaluation. |
| ln Vivo |
In vivo activity data for Fmoc-Lys-OAll.HCl as a standalone compound is not applicable. It is a protected amino acid building block used in research. Peptides synthesized using this building block may be evaluated in animal models. The allyl ester protecting group is typically removed before biological testing.
|
| Enzyme Assay |
In vitro SPPS protocols for Fmoc-Lys-OAll.HCl involve standard Fmoc chemistry. The compound is activated with coupling reagents and DIPEA in DMF, then coupled to resin-bound peptides. Fmoc deprotection uses 20% piperidine in DMF. The allyl ester is removed by palladium-catalyzed deallylation. Purity is typically ≥98% by HPLC. Solubility in DMSO is ≥80 mg/mL.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Fmoc-Lys-OAll.HCl as it is a protected amino acid derivative. Lysine-containing peptides synthesized using this reagent can be tested in cell culture after deprotection. Peptides are dissolved in DMSO or appropriate buffers and added to cells at concentrations of 0.1-100 µM for 24-72 hours.
|
| Animal Protocol |
Animal studies with Fmoc-Lys-OAll.HCl are not conducted directly. Peptides containing lysine residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-Lys-OAll.HCl as a standalone compound is not applicable. The compound has a molecular weight of 444.95 g/mol, formula C24H29ClN2O4, and CAS number 815619-80-8. It appears as a solid. Storage is recommended at 4°C, sealed. Solubility in DMSO is ≥80 mg/mL.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for Fmoc-Lys-OAll.HCl. The compound is for research use only. Standard safety precautions should be observed. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Fmoc-Lys-OAll.HCl (CAS#: 815619-80-8) is also known as Nα-Fmoc-L-lysine allyl ester hydrochloride and (S)-allyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-6-aminohexanoate hydrochloride. It is a lysine analogue used in peptide synthesis. It has no approved therapeutic indications.
|
| Molecular Formula |
C24H29CLN2O4
|
|---|---|
| Molecular Weight |
444.95106
|
| Exact Mass |
444.181
|
| CAS # |
815619-80-8
|
| PubChem CID |
71607445
|
| Appearance |
White to yellow powder
|
| LogP |
5.458
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
31
|
| Complexity |
560
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(C1C2C=CC=CC=2C2C=CC=CC1=2)OC(=O)N[C@@H](CCCCN)C(=O)OCC=C.Cl
|
| InChi Key |
IBCYYPRTIQUQJP-FTBISJDPSA-N
|
| InChi Code |
InChI=1S/C24H28N2O4.ClH/c1-2-15-29-23(27)22(13-7-8-14-25)26-24(28)30-16-21-19-11-5-3-9-17(19)18-10-4-6-12-20(18)21;/h2-6,9-12,21-22H,1,7-8,13-16,25H2,(H,26,28);1H/t22-;/m0./s1
|
| Chemical Name |
prop-2-enyl (2S)-6-amino-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoate;hydrochloride
|
| Synonyms |
Fmoc-Lys-OAll.HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~224.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2474 mL | 11.2372 mL | 22.4744 mL | |
| 5 mM | 0.4495 mL | 2.2474 mL | 4.4949 mL | |
| 10 mM | 0.2247 mL | 1.1237 mL | 2.2474 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
